Cancer Chemother Pharmacol (2014) 73:435–436 DOI 10.1007/s00280-013-2331-6
COMMENTARY
Assessing physico‑chemical compatibility of concomitantly diluted antiemetics including palonosetron‑HCl and fosaprepitant dimeglumine Hans‑Peter Lipp · Wieland Gfrörer
Received: 16 August 2013 / Accepted: 16 October 2013 / Published online: 13 November 2013 © Springer-Verlag Berlin Heidelberg 2013
Very recently, Sun et al. [1] presented physico-chemical compatibility data of intravenous fosaprepitant with different 5-HT3 antagonists and corticosteroids in the same infusion solution. After 24-h storage under ambient conditions, samples were assayed for degradation. Compatibility was defined as (1) 0.2 % in degradation level as unacceptable which is somewhat surprising. It is convenient, to accept a limit up to even 10 % decrease in the parent compound, when stability and compatibility are monitored during experimental studies (e.g., ondansetron-HCl and dexamethasone sodium phosphate in infusion bags and syringes for 32 days), however, with non-toxic, inactive degradation products as a prerequisite [3, 4]. In contrast, such a limit is deeply unacceptable in the case of dacarbazine based on the fact that already small amounts, e.g.,
COMMENTARY
Assessing physico‑chemical compatibility of concomitantly diluted antiemetics including palonosetron‑HCl and fosaprepitant dimeglumine Hans‑Peter Lipp · Wieland Gfrörer
Received: 16 August 2013 / Accepted: 16 October 2013 / Published online: 13 November 2013 © Springer-Verlag Berlin Heidelberg 2013
Very recently, Sun et al. [1] presented physico-chemical compatibility data of intravenous fosaprepitant with different 5-HT3 antagonists and corticosteroids in the same infusion solution. After 24-h storage under ambient conditions, samples were assayed for degradation. Compatibility was defined as (1) 0.2 % in degradation level as unacceptable which is somewhat surprising. It is convenient, to accept a limit up to even 10 % decrease in the parent compound, when stability and compatibility are monitored during experimental studies (e.g., ondansetron-HCl and dexamethasone sodium phosphate in infusion bags and syringes for 32 days), however, with non-toxic, inactive degradation products as a prerequisite [3, 4]. In contrast, such a limit is deeply unacceptable in the case of dacarbazine based on the fact that already small amounts, e.g.,
